. 2024 Aug 31;30(2):104–119. doi: 10.6118/jmm.23015

Table 2. mRNA fold-changes in the genes analyzed with quantitative real-time polymerase chain reaction in ovary tissue.

Gene		AP39		Cisplatin		Cisplatin + AP39		CIS		CIS + AP39
Gene		mRNA fold change	P	mRNA fold change	P	mRNA fold change	P	mRNA fold change	P	mRNA fold change	P
GAPDH		1	0	1	0	1	0	1	0	1	0
Mitochondrial function related genes
	MFN2	2.82^a	0.02	3.03^a	0.020	1.65	0.11	2.31	0.04	1.68	0.110
	NRF1	1.08	0.74	0.99	0.978	0.45	0.04	1.39	0.26	0.60	0.113
	ATP5B	2.42^a	0.033	3.36^a	0.017	1.46^c	0.199	1.57	0.15	2.07	0.034
	TFAM	2.12^a	0.048	2.20^a	0.043	0.67	0.187	1.96	0.06	1.13	0.651
	PPARGC1A	0.06^a	0.00	0.18^a	0.009	0.17	0.009	0.18	0.01	0.24	0.012
	CHRM1	20.82^a	0.005	0.93^b	0.788	0.40^bc	0.030	8.69^b	0.01	6.06^bd	0.008
	HIF1A	1.01	0.978	3.66^ab	0.015	5.10^ab	0.010	3.39^ab	0.02	9.38^abd	0.006
	OPA1	8.34^a	0.007	9.51^a	0.006	4.14^bc	0.012	6.54^b	0.01	6.59^b	0.008
	PRKAA2	0.50^a	0.048	0.45^a	0.042	0.43^a	0.038	0.40^a	0.03	0.53	0.072
	MFN1	1.19	0.514	1.12	0.651	0.63	0.138	0.83	0.48	0.71	0.240
	NFE2L2	2.66^a	0.027	2.23^a	0.041	2.19^a	0.044	2.62^a	0.03	2.55^a	0.029
	PPARGC1B	1.10	0.728	0.75	0.310	0.22	0.011	0.46	0.05	0.97	0.892
Ovarian function related genes
	DPPA3	0.18^a	0.009	0.12^a	0.007	0.08^a	0.006	0.10^a	0.01	0.01^a	0.004
	FIGLA	1.71	0.104	1.49	0.181	0.31^a	0.018	1.40^a	0.24	1.91	0.069
	DAZL	16.22^a	0.005	15.67^a	0.005	8.06^abc	0.007	15.35^a	0.01	3.46^ad	0.016
	ZP1	4.79^a	0.010	2.00^ab	0.038	0.45^ab	0.042	12.82^ab	0.01	4.06^ad	0.013
	ZP2	10.82^a	0.006	13.36^ab	0.006	25.99^abc	0.005	71.51^ab	0.00	16.11^abd	0.005
	POU5F1	1.13	0.633	0.71	0.248	0.11^a	0.007	1.54	0.16	0.75	0.310
	NPM2	13.09^a	0.006	26.72^ab	0.005	4.35^abc	0.012	25.28^ab	0.00	31.78^abd	0.005
	H1FOO	4.14^a	0.012	3.20^a	0.018	8.69^abc	0.007	6.82^a	0.01	4.96^ad	0.010
	DNMT1	11.31^a	0.005	12.30^a	0.006	14.72^ab	0.006	15.89^ab	0.01	13.83^ab	0.006
	DNMT3B	5.13^a	0.010	5.66^a	0.009	17.15^abc	0.005	5.10^a	0.01	6.19^a	0.008
	KAT2A	12.82^a	0.006	17.27^ab	0.005	42.22^abc	0.005	19.70^ab	0.01	20.97^ab	0.005
	HDAC3	10.56^a	0.006	11.47^a	0.006	63.12^abc	0.004	24.08^ab	0.00	15.24^abd	0.005
	SIRT7	12.64^a	0.006	14.03^a	0.006	54.95^abc	0.005	22.94^ab	0.00	18.50^abd	0.005
	MBD2	8.00^a	0.007	10.56^ab	0.006	114.56^abc	0.004	15.67^ab	0.01	3.51^abd	0.016
	KMT2A	2.53^a	0.03	3.71^a	0.014	4.59^ab	0.011	3.89^a	0.01	2.54^a	0.03
	SMARCA1	2.40^a	0.034	1.180	0.53	2.89^ac	0.022	2.25^a	0.04	1.60	0.134
	ESR1	82.71^a	0.004	78.25^a	0.004	221.32^abc	0.004	380.04^ab	0.00	124.50^abd	0.004
	MAP2K1	99.73^a	0.004	116.97^ab	0.004	130.69^abc	0.004	187.40^ab	0.00	77.71^abd	0.004
	NCOA1	2.00^a	0.039	1.870	0.07	0.13^abc	0.007	0.13^ab	0.01	0.73^bd	0.264
	TBP	0.52	0.07	0.30^a	0.017	0.24^a	0.012	0.10^a	0.01	0.15^a	0.007
	POLR2C	4.99^a	0.01	4.89^a	0.01	4.40^a	0.014	3.65^a	0.014	4.19^a	0.012
	GTF2H1	0.25^a	0.01	0.16^ab	0.01	3.27^abc	0.017	0.18^a	0.009	0.16^a	0.008

Data presented as mean ± standard deviation.

CIS: chronic immobilization stress.

^aStatistically significant difference from the control group.

^bStatistically significant difference from the AP39 group.

^cStatistically significant difference from the Cisplatin group.

^dStatistically significant difference from the CIS group. P < 0.05: versus control group.